Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jerome Filippi, Janneke Vander Woude, Philippe Van Hootegem, Jacques Moreau, Edouard Louis, Denis Franchimont, Martine De Vos, Fazia Mana, Laurent Peyrin-Biroulet, Hedia Brixi, Matthieu Allez, Philip CaenepeelAlexandre Aubourg, Bas Oldenburg, Marieke Pierik, Ann Gils, Sylvie Chevret, David Laharie, GETAID

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1343-1351.e1
Number of pages10
JournalGastroenterology
Volume154
Issue number5
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Crohn's Disease
  • Therapeutic Drug Monitoring
  • Infliximab
  • Mucosal Healing
  • INFLAMMATORY-BOWEL-DISEASE
  • SCHEDULED MAINTENANCE TREATMENT
  • RANDOMIZED-TRIAL
  • TROUGH LEVEL
  • ANTIBODIES
  • THERAPY
  • INTENSIFICATION
  • MULTICENTER
  • OUTCOMES

Cite this

D'Haens, G., Vermeire, S., Lambrecht, G., Baert, F., Bossuyt, P., Pariente, B., Buisson, A., Bouhnik, Y., Filippi, J., Vander Woude, J., Van Hootegem, P., Moreau, J., Louis, E., Franchimont, D., De Vos, M., Mana, F., Peyrin-Biroulet, L., Brixi, H., Allez, M., ... GETAID (2018). Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology, 154(5), 1343-1351.e1. https://doi.org/10.1053/j.gastro.2018.01.004